Literature DB >> 1727135

In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography.

K A Frey1, R A Koeppe, G K Mulholland, D Jewett, R Hichwa, R L Ehrenkaufer, J E Carey, D M Wieland, D E Kuhl, B W Agranoff.   

Abstract

Cerebral muscarinic cholinergic receptors were imaged and regionally quantified in vivo in humans with the use of [11C]scopolamine and positron emission tomography. Previous studies in experimental animals have suggested the utility of radiolabeled scopolamine for in vivo measurements, on the bases of its maintained pharmacologic specificity following systemic administration and the exclusion of labeled metabolites from the brain. The present studies describe the cerebral distribution kinetics of [11C]scopolamine in normal subjects following intravenous injection. Scopolamine is initially delivered to brain in a perfusion-directed pattern. After 30 to 60 min, activity is lost preferentially from cerebral structures with low muscarinic receptor density including the cerebellum and thalamus. Activity continues to accumulate throughout a 2 h postinjection period in receptor-rich areas including cerebral cortex and the basal ganglia. The late regional concentration of [11C]scopolamine does not, however, accurately parallel known differences in muscarinic receptor numbers in these receptor-rich areas. Tracer kinetic analysis of the data, performed on the basis of a three-compartment model, provides receptor binding estimates in good agreement with prior in vitro measurements. Kinetic analysis confirms significant contributions of ligand delivery and extraction to the late distribution of [11C]scopolamine, reconciling the discrepancy between receptor levels and tracer concentration. Finally, a novel dual-isotope method for rapid chromatographic processing of arterial blood samples in radiotracer studies is presented. The combination of rapid chromatography and compartmental analysis of tracer distribution should have broad utility in future in vivo studies with short-lived radioligands.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727135     DOI: 10.1038/jcbfm.1992.18

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  19 in total

1.  Pharmacological modulation of behavioral and neuronal correlates of repetition priming.

Authors:  C M Thiel; R N Henson; J S Morris; K J Friston; R J Dolan
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

2.  Why does the agonist [(18)F]FP-TZTP bind preferentially to the M(2) muscarinic receptor?

Authors:  L Ravasi; D O Kiesewetter; K Shimoji; G Lucignani; W C Eckelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12-07       Impact factor: 9.236

3.  Quantitative in vivo receptor binding. IV: Detection of muscarinic receptor down-regulation by equilibrium and by tracer kinetic methods.

Authors:  K A Frey; B Ciliax; B W Agranoff
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

Review 4.  Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography.

Authors:  Peter Brust; Jörg van den Hoff; Jörg Steinbach
Journal:  Neurosci Bull       Date:  2014-08-29       Impact factor: 5.203

5.  Basal forebrain moderates the magnitude of task-dependent amygdala functional connectivity.

Authors:  Adam X Gorka; Annchen R Knodt; Ahmad R Hariri
Journal:  Soc Cogn Affect Neurosci       Date:  2014-05-19       Impact factor: 3.436

6.  Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.

Authors:  Ricardo Alvarez-Jimenez; Geert Jan Groeneveld; Joop M A van Gerven; Sebastiaan C Goulooze; Anne Catrien Baakman; Justin L Hay; Jasper Stevens
Journal:  Br J Clin Pharmacol       Date:  2016-07-14       Impact factor: 4.335

7.  Scopolamine disrupts place navigation in rats and humans: a translational validation of the Hidden Goal Task in the Morris water maze and a real maze for humans.

Authors:  Jan Laczó; Hana Markova; Veronika Lobellova; Ivana Gazova; Martina Parizkova; Jiri Cerman; Tereza Nekovarova; Karel Vales; Sylva Klovrzova; John Harrison; Manfred Windisch; Kamil Vlcek; Jan Svoboda; Jakub Hort; Ales Stuchlik
Journal:  Psychopharmacology (Berl)       Date:  2016-11-24       Impact factor: 4.530

8.  A reappraisal of the relative merits of SPET and PET in the quantitation of neuroreceptors: the advantage of a longer half-life!

Authors:  N A Lassen
Journal:  Eur J Nucl Med       Date:  1996-01

9.  The metabolic brain pattern of young subjects given scopolamine.

Authors:  R M Cohen; M Gross; W E Semple; T E Nordahl; T Sunderland
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

Review 10.  Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.

Authors:  Wayne C Drevets; Carlos A Zarate; Maura L Furey
Journal:  Biol Psychiatry       Date:  2012-11-28       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.